Personalized and translational approach for malignant brain tumors in the era of precision medicine: the strategic contribution of an experienced neurosurgery laboratory in a modern neurosurgery and neuro-oncology department.

Publication date: Aug 06, 2020

Personalized medicine (PM) aims to optimize patient management, taking into account the individual traits of each patient. The main purpose of PM is to obtain the best response, improving health care and lowering costs. Extending traditional approaches, PM introduces novel patient-specific paradigms from diagnosis to treatment, with greater precision. In neuro-oncology, the concept of PM is well established. Indeed, every neurosurgical intervention for brain tumors has always been highly personalized. In recent years, PM has been introduced in neuro-oncology also to design and prescribe specific therapies for the patient and the patient’s tumor. The huge advances in basic and translational research in the fields of genetics, molecular and cellular biology, transcriptomics, proteomics, and metabolomics have led to the introduction of PM into clinical practice. The identification of a patient’s individual variation map may allow to design selected therapeutic protocols that ensure successful outcomes and minimize harmful side effects. Thus, clinicians can switch from the “one-size-fits-all” approach to PM, ensuring better patient care and high safety margin. Here, we review emerging trends and the current literature about the development of PM in neuro-oncology, considering the positive impact of innovative advanced researches conducted by a neurosurgical laboratory.

Concepts Keywords
Brain Tumors Selected therapeutic protocols
Cellular Biology Patient management
Department Neurosurgery
Genetics Medical specialties
Malignant Neurosurgery
Metabolomics Medicine
Neurosurgery Brain tumor
Neurosurgical Clinical medicine
Oncology Draft:Society for NeuroOncology
Precision Medicine Isabelle M. Germano
Proteomics Transcriptomics
Sci Proteomics
Transcriptomics Neurosurgery
Tumor Metabolomics
Selected therapeutic protocols


Type Source Name
disease MESH brain tumors
disease MESH diagnosis
disease MESH tumor
drug DRUGBANK Tropicamide
disease MESH development
disease MESH Glioblastoma

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *